Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Acquisitions & Divestments (2015 - 2016)

Cytosorbents posted quarterly Change in Acquisitions & Divestments of $249000.0 for Q3 2016, down 83.33% year-on-year from $1.5 million in Q4 2015, and down 87.18% on a QoQ basis from $1.9 million in Q2 2016.

Cytosorbents (CTSO) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $249000.0 in Q3 2016.

  • For the quarter ending Q3 2016, Change in Acquisitions & Divestments fell 83.33% year-over-year to $249000.0; the trailing twelve-month figure through Dec 2017 stood at $2.2 million (changed 0.0% YoY), and the FY2016 full-year result was $2.2 million, down 59.64% from the prior year.
  • Change in Acquisitions & Divestments for Q3 2016 stood at $249000.0, down from $1.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.9 million in Q2 2016 and bottomed at $249000.0 in Q3 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Cytosorbents 28.81 Mn 24.01 Mn 6.13 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2016 249,000.00
Sep 30, 2016 249,000.00
Jun 30, 2016 1.94 Mn
Jun 30, 2016 1.94 Mn
Dec 31, 2015 1.49 Mn
Dec 31, 2015 1.49 Mn
Sep 30, 2015 1.49 Mn
Sep 30, 2015 1.49 Mn
Jun 30, 2015 1.20 Mn
Jun 30, 2015 1.20 Mn
Mar 31, 2015 1.25 Mn
Mar 31, 2015 1.25 Mn